Related Experiment Videos
Epstein-Barr virus (EBV) infection in infancy
K H Chan1, J S Tam, J S Peiris
1Department of Microbiology, Queen Mary Hospital, Hong Kong, Special Administrative Region, China. dkhchan@netvigator.com
Summary
Primary Epstein-Barr virus (EBV) infection in infants is usually asymptomatic, with maternal antibodies potentially delaying and containing the infection. Understanding this pattern is crucial for developing an effective EBV vaccine.
Area of Science:
- Pediatric Infectious Diseases
- Virology
- Immunology
Background:
- Epstein-Barr virus (EBV) causes infectious mononucleosis and is linked to various cancers, necessitating vaccine development.
- Primary EBV infection in infancy is typically mild or asymptomatic, with limited understanding of its serological patterns.
- Infant EBV infection epidemiology is vital for effective vaccine strategies.
Purpose of the Study:
- To elucidate the epidemiology and serology of primary EBV infection in early infancy.
- To investigate the influence of maternal antibodies on infant EBV infection dynamics.
Main Methods:
- Longitudinal serum samples from 66 Hong Kong infants were collected from birth to 2 years of age.
- Samples were tested for EBV antibodies using immunofluorescence.
- Serological testing included cord blood and sequential samples at 4-month intervals.
Main Results:
- Maternal antibodies were detected in all cord blood samples and some 4-month-old infants.
- 60.6% of infants showed EBV infection (VCA-IgG seroconversion) within the first two years.
- Infection onset was delayed until after 8 months, then occurred at a steady rate.
Conclusions:
- Maternal antibodies appear to play a protective role, delaying primary EBV infection onset in infants.
- Persistent maternal antibodies may help contain EBV infection, contributing to asymptomatic primary infection in infancy.
- The delayed and contained infection pattern in infancy contrasts with adolescent infections and informs vaccine approaches.